{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T10:24:17Z","timestamp":1783247057871,"version":"3.54.6"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007787","name":"National Research Centre","doi-asserted-by":"publisher","award":["12010103"],"award-info":[{"award-number":["12010103"]}],"id":[{"id":"10.13039\/100007787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bioorg.2021.105421","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T12:10:26Z","timestamp":1633954226000},"page":"105421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Synthesis, biological evaluation and molecular docking of new sulfonamide-based indolinone derivatives as multitargeted kinase inhibitors against leukemia"],"prefix":"10.1016","volume":"117","author":[{"given":"Marwa","family":"El-Hussieny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naglaa F.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa A.","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewies F.","family":"Ewies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.105421_b0005","article-title":"Constructions of cancer in early modern England: ravenous natures, Springer","author":"Skuse","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bioorg.2021.105421_b0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"20","key":"10.1016\/j.bioorg.2021.105421_b0015","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1001\/jama.291.20.2471","article-title":"Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area","volume":"291","author":"Howard","year":"2004","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.bioorg.2021.105421_b0020","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA oncology"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105421_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-48445-1","article-title":"An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States","volume":"9","author":"Hao","year":"2019","journal-title":"Sci. Rep."},{"issue":"15","key":"10.1016\/j.bioorg.2021.105421_b0030","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.ejca.2011.12.028","article-title":"Simultaneous inhibition of Src and Aurora kinases by SU6656 induces therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo","volume":"48","author":"Arai","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2021.105421_b0035","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ejmech.2019.06.002","article-title":"Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade","volume":"178","author":"Yuan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105421_b0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd2683","article-title":"Mechanisms of drug combinations: interaction and network perspectives","volume":"8","author":"Jia","year":"2009","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105421_b0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/138955712798995039","article-title":"Indolinones as promising scaffold as kinase inhibitors: a review","volume":"12","author":"Prakash","year":"2012","journal-title":"Mini reviews in medicinal chemistry"},{"key":"10.1016\/j.bioorg.2021.105421_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104985","article-title":"Insight on a new indolinone derivative as an orally bioavailable lead compound against renal cell carcinoma","volume":"112","author":"Fouad","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105421_b0055","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/B978-0-12-397220-0.00009-X","article-title":"Sunitinib malate","volume":"37","author":"Kassem","year":"2012","journal-title":"Profiles of Drug Substances, Excipients and Related Methodology"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105421_b0060","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105421_b0065","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bioorg.2019.01.016","article-title":"Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers","volume":"85","author":"El-Sharief","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105421_b0070","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1158\/1535-7163.MCT-09-0765","article-title":"Aurora kinase inhibitors-rising stars in cancer therapeutics?","volume":"9","author":"Dar","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105421_b0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2011.08898.x","article-title":"The potential role of Aurora kinase inhibitors in haematological malignancies","volume":"155","author":"Farag","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105421_b0080","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-07-2179","article-title":"Aurora kinases as anticancer drug targets","volume":"14","author":"Gautschi","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"10-12","key":"10.1016\/j.bioorg.2021.105421_b0085","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.bbagrm.2010.09.004","article-title":"Aurora kinase inhibitors as anticancer molecules","volume":"1799","author":"Katayama","year":"2010","journal-title":"Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105421_b0090","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2174\/157489208784638785","article-title":"Aurora kinase family: a new target for anticancer drug","volume":"3","author":"Macarulla","year":"2008","journal-title":"Recent Pat. Anti-Cancer Drug Discovery"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105421_b0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ctrv.2007.09.005","article-title":"Aurora kinases as targets for cancer therapy","volume":"34","author":"Mountzios","year":"2008","journal-title":"Cancer Treat. Rev."},{"issue":"16","key":"10.1016\/j.bioorg.2021.105421_b0100","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2174\/092986709788682227","article-title":"Small molecule aurora kinases inhibitors","volume":"16","author":"Garuti","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105421_b0105","doi-asserted-by":"crossref","unstructured":"C.H.A. Cheung, M.S. Coumar, J.-Y. Chang, H.-P. Hsieh, Aurora kinase inhibitor patents and agents in clinical testing: an update (2009\u201310) This article is an update to aurora kinase inhibitors review, which appeared in: Expert Opin. Ther. Patents 2009, 19, 1-36 and Expert Opin. Investig. Drugs 2009, 18, 1-20, Expert opinion on therapeutic patents 21(6) (2011) 857-884.","DOI":"10.1517\/13543776.2011.574614"},{"issue":"4","key":"10.1016\/j.bioorg.2021.105421_b0110","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/13543780902806392","article-title":"Aurora kinase inhibitors in preclinical and clinical testing","volume":"18","author":"Cheung","year":"2009","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"6","key":"10.1016\/j.bioorg.2021.105421_b0115","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s10637-012-9798-6","article-title":"Aurora kinase inhibitors: progress towards the clinic","volume":"30","author":"Kollareddy","year":"2012","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105421_b0120","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1083\/jcb.200208092","article-title":"The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore\u2013microtubule attachment and in maintaining the spindle assembly checkpoint","volume":"161","author":"Hauf","year":"2003","journal-title":"J. Cell Biol."},{"issue":"15","key":"10.1016\/j.bioorg.2021.105421_b0125","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1158\/0008-5472.CAN-05-0574","article-title":"Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling","volume":"65","author":"Godl","year":"2005","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.bioorg.2021.105421_b0130","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1021\/jm1001869","article-title":"Discovery of pyrrole\u2212 indoline-2-ones as Aurora kinase inhibitors with a different inhibition profile","volume":"53","author":"Chiang","year":"2010","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105421_b0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.leu.2404064","article-title":"Chronic myeloproliferative disorders: a tyrosine kinase tale","volume":"20","author":"De Keersmaecker","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2021.105421_b0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejmech.2014.03.027","article-title":"Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors","volume":"78","author":"Luo","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105421_b0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejmech.2017.04.037","article-title":"Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia","volume":"135","author":"Liu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2021.105421_b0150","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1158\/0008-5472.CAN-05-0882","article-title":"The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases","volume":"65","author":"Emanuel","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105421_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104849","article-title":"Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia","volume":"111","author":"Feng","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105421_b0160","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1021\/ja01379a043","article-title":"Identification of amines. IV. Methanesulfonamides","volume":"51","author":"Marvel","year":"1929","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105421_b0165","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/0039-9140(67)80226-1","article-title":"Sur la d\u00e9termination des chaleurs de neutralisation de quelques amines aliphatiques par le titrage enthalpim\u00e9trique","volume":"14","author":"Popper","year":"1967","journal-title":"Talanta"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105421_b0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF01404408","article-title":"A rapid and simple MTT-based spectrophotometric assay for determining drug sensitivity in monolayer cultures","volume":"11","author":"Edmondson","year":"1988","journal-title":"Journal of tissue culture methods"},{"issue":"3","key":"10.1016\/j.bioorg.2021.105421_b0175","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.critrevonc.2014.10.007","article-title":"Angiogenic factors in chronic lymphocytic leukaemia (CLL): Where do we stand?","volume":"93","author":"Palma","year":"2015","journal-title":"Critical reviews in oncology\/hematology"},{"issue":"18","key":"10.1016\/j.bioorg.2021.105421_b0180","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1016\/j.bmcl.2008.07.090","article-title":"7-[1H-Indol-2-yl]-2, 3-dihydro-isoindol-1-ones as dual Aurora-A\/VEGF-R2 kinase inhibitors: Design, synthesis, and biological activity","volume":"18","author":"Hughes","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105421_b0185","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.bmc.2006.12.011","article-title":"Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis (benzo [b] furan-2-yl) methanones","volume":"15","author":"Mahboobi","year":"2007","journal-title":"Bioorg. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2021.105421_b0190","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/cbic.201200316","article-title":"A novel approach to the discovery of small molecule ligands of CDK2","volume":"13","author":"Martin","year":"2012","journal-title":"Chembiochem: a European journal of chemical biology"},{"key":"10.1016\/j.bioorg.2021.105421_b0195","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fonc.2015.00285","article-title":"A cell biologist\u2019s field guide to aurora kinase inhibitors","volume":"5","author":"de Groot","year":"2015","journal-title":"Front. Oncol."},{"issue":"15","key":"10.1016\/j.bioorg.2021.105421_b0200","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1021\/jo00391a067","article-title":"Kinetic resolutions of aliphatic alcohols with a fungal lipase from Mucor miehei","volume":"52","author":"Sonnet","year":"1987","journal-title":"The Journal of Organic Chemistry"},{"issue":"20","key":"10.1016\/j.bioorg.2021.105421_b0205","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1055\/s-0034-1379483","article-title":"Cyanation of Unactivated Aryl Chlorides and Aryl Mesylates Catalyzed by Palladium and Hemilabile MOP-Type Ligands","volume":"25","author":"Tu","year":"2014","journal-title":"Synlett"},{"issue":"18","key":"10.1016\/j.bioorg.2021.105421_b0210","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1002\/ejoc.201402120","article-title":"Suzuki-Miyaura Coupling of Aryl Sulfonates with Arylboronic Acids Using a Morpholine\u2013Pd (OAc) 2 Catalyst System","volume":"2014","author":"Abe","year":"2014","journal-title":"Eur. J. Org. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2021.105421_b0215","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","article-title":"Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines","volume":"83","author":"Monks","year":"1991","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"2","key":"10.1016\/j.bioorg.2021.105421_b0220","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ddr.430340203","article-title":"Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen","volume":"34","author":"Boyd","year":"1995","journal-title":"Drug Dev. Res."},{"issue":"21","key":"10.1016\/j.bioorg.2021.105421_b0225","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.1984","article-title":"Sulforhodamine B (SRB) assay in cell culture to investigate cell proliferation","volume":"6","author":"Orellana","year":"2016","journal-title":"Bio-protocol"},{"key":"10.1016\/j.bioorg.2021.105421_b0230","series-title":"Analysis of cell cycle by flow cytometry, Checkpoint controls and cancer","first-page":"301","author":"Pozarowski","year":"2004"},{"key":"10.1016\/j.bioorg.2021.105421_b0235","doi-asserted-by":"crossref","unstructured":"L.C. Crowley, A.P. Scott, B.J. Marfell, J.A. Boughaba, G. Chojnowski, N.J. Waterhouse, Measuring cell death by propidium iodide uptake and flow cytometry, Cold Spring Harbor Protocols 2016(7) (2016) pdb. prot087163.","DOI":"10.1101\/pdb.prot087163"},{"issue":"42","key":"10.1016\/j.bioorg.2021.105421_b0240","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.2174\/0929867325666180622143548","article-title":"Rational drug design approach of receptor tyrosine kinase type III inhibitors","volume":"26","author":"Kim","year":"2020","journal-title":"Curr. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821007987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821007987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:55:13Z","timestamp":1777463713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821007987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":48,"alternative-id":["S0045206821007987"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105421","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, biological evaluation and molecular docking of new sulfonamide-based indolinone derivatives as multitargeted kinase inhibitors against leukemia","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105421"}}